IBB News 275.23 09/22/2014 05:04:27 Nasdaq Biotechnology Ishares

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 275.23 $IBB

'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.

iShares Nasdaq Biotechnology Index Falls 1.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $263.64 to a high of $268.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $268.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched  iShares Nasdaq Biotechnology Index   pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...

WIT, IBB, EROC, MPX, SEP, TUZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Wipro Ltd (NYSE:WIT), Ishares Nasdaq Biotechnology (NASDAQ:IBB), EAGLE ROCK ENERGY PARTNERS (NASDAQ:EROC), Marine Products Corp (NYSE:MPX), Spectra Energy Partners LP (NYSE:SEP), PimCo 1 3 Year Us Treasury Index Fund (NYSE:TUZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

After Yesterday's Rally of 1.85% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 10, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 1.85%
Comtex SmarTrend(R) - Wed Sep 10, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 39

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 46

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 48

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 44

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 50

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 61

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 58

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Cemtrex's Stock Surge Sparks Interest in Leading Movers

Updated Category News Views 117

Cemtrex Experiences Notable Share Surge Shares of Cemtrex, Inc. CETX have seen a significant uptick amid pre-market trading. This boost comes on the heels of better-than-expected sales in the latest quarter, reporting an impressive $18.10 million in sales, surpassing the general analyst expectation of $16.39 million. This remarkable performance in sales has sparked...

Continue Reading
Exciting New PharmD-MBA Pathway Combines Pharmacy and Business

Updated Category News Views 193

Collaboration between Cal Poly Pomona and Western University In an exciting move, Cal Poly Pomona's Singelyn Graduate School of Business and Western University of Health Sciences have teamed up to create a groundbreaking pathway for aspiring healthcare professionals. This innovative PharmD-MBA program combines the fields of pharmacy and business, providing a unique...

Continue Reading
Kaskela Law Investigates Stock Misconduct in Stanley Black & Decker

Updated Category News Views 155

Overview of the Investigation by Kaskela Law LLC Kaskela Law LLC has announced an important investigation focused on Stanley Black & Decker, Inc. (NYSE: SWK) concerning allegations of potential securities fraud. This inquiry is primarily aimed at safeguarding the interests of long-term investors who hold shares in this well-known manufacturing company. Details Surrounding...

Continue Reading
Legend Biotech's Carvykti: A Leading Force in Cancer Treatment

Updated Category News Views 90

Redburn's Positive Outlook for Legend Biotech Recently, Redburn-Atlantic began covering Legend Biotech Corp. (NASDAQ: LEGN) with a favorable Buy rating and set a price target of $86.00 for the stock. This biotechnology company has made significant strides, particularly with the recent approval of its innovative product, Carvykti, designed for the treatment of multiple...

Continue Reading
Transforming the Anti-Obesity Drug Market for Future Success

Updated Category News Views 132

Global Anti-Obesity Drug Market Overview As global health concerns rise, the demand for anti-obesity drugs is surging. Recent reports estimate that the anti-obesity drug market will soar to USD 82.55 billion in the coming years. This impressive growth, fueled by an anticipated compound annual growth rate (CAGR) of 18.01%, signals a crucial moment for pharmaceutical...

Continue Reading